Side effect(s) of Avelumab

Review the side-effects of Avelumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

Fatigue , infusion-related reactions that include fever, chills, hypotension and wheezing, peripheral edema

Abdominal pain, diarrhea, nausea, vomiting, constipation

  Central nervous system:
Headache, dizziness

Cough, difficulty in breathing

Increased blood pressure, heartbeat abnormalities, lightheadedness when getting up suddenly from lying or sitting position

Rashes and itching

Arthralgia and muscle pain

Nephritis, renal dysfunction

Inflammation of the heart, lung, colon, liver, endocrine organs, diabetes, muscle, brain, blood vessels, psoriasis, arthritis, skin reactions

vision problems, reduced appetite, reduced weight, loss of weight

Other Precautions :

• Patients should be advised to report to an emergency center in case of serious immune-mediated adverse reactions or infusion-related reactions.
• Breastfeeding mothers must be informed not to breastfeed during avelumab therapy and also until 1 month after the final dose of avelumab.

Drug Name : Avelumab

Avelumab generic Avelumab is a programmed death ligand-1 (PD-L1) blocking antibody which is prescribed to treat adult and pediatric patients of 12 years and older who suffer from advanced Merkel-cell carcinoma that has spread to other parts of the body. Merkel-cell carcinoma is a rare but highly aggressive form of skin cancer caused by the Merkel cell polyomavirus. Avelumab is also used to treat urothelial cancer (cancer that occurs in the bladder, ureter, and urethra) in patients whose cancer was worsened during chemotherapy or within 12 months of chemotherapy given with surgery. It received orphan drug designation in January 2017 by the European Medicines Agency (EMA) for treating stomach cancer. Avelumab acts either by slowing down the growth of cancer cells or stops the further development of cancer. It works by helping to stop cancer cells from growing.

Recommended Reading